

reduction of serum calcium levels.

Several recent reports have indicated that soy, a rich source of isoflavone genistein and daidzein, has a beneficial effect, reducing bone loss associated with ovarian hormone deficiency [5–7]. Soy isoflavone treatment induced a large increase in bone mineral density (BMD) in ovariectomized rats [8] and mice [5]. Postmenopausal women with habitually high intakes of dietary isoflavones had significantly lower levels of serum PTH and higher BMD [6]. In an *in vitro* study, the decrease in bone calcium content induced by bone resorbing factors, PTH, and prostaglandins E₂ was inhibited completely by genistein [9]. Moreover, genistein blocked both the inactivation of acid phosphatase and the activation of alkaline phosphatase due to PTH in bone tissue, resulting in reduced bone resorption in rats [10]. The evidence strongly suggests that phytoestrogens play a role in preventing bone loss caused by estrogen deficiency in women as well as female animals, possibly through the reduction of PTH levels.

Pueraria mirifica (PM), known as White Kwao Krua, is an indigenous Thai plant that has long been used as a rejuvenating drug. The chemical content of its tuberous roots has been analyzed by high performance liquid chromatography and many phytoestrogenic substances were found, including miroestrol [11, 12], deoxymiroestrol, kwakhurin [13], coumestrol, and isoflavones (genistein and daidzein) [14, 15]. Several investigators have studied PM's estrogenic effect on the reproductive organs and their functions [16–18]. Prior research found a PM effect using an animal model [16–18]. Treatment with a suspension of PM at various doses influenced serum gonadotropin levels in both aged menopausal and adult cyclic cynomolgus monkeys [18, 19]. One study found that administration of crude extract of PM improved menopause-related symptoms in women such as hot flashes, frustration, sleep disorder, skin dryness, high blood cholesterol, and amenorrhea with no change in blood cells, or liver or renal functions [20]. No research, however, has studied the effects of PM on bone, calcium, or PTH levels. This is of interest for female animals and menopausal women who face bone disorder problems. The aim of this study, therefore, was to investigate the estrogenic effect of long-term treatment of PM on serum levels of PTH and calcium in aged menopausal monkeys. Aged

menopausal cynomolgus monkeys were used in this study as a representative of menopausal women, because the physiological systems of cynomolgus monkeys, including hormonal patterns and reproductive function, are similar to those of humans [21, 22].

Materials and Methods

Animals

Aged menopausal monkeys (*Macaca fascicularis*, n=9) with a complete cessation of menstruation for at least one year, age more than 25 years, and weighing from 4.0–6.5 kg, were selected. The menopausal state of the monkeys was confirmed and checked daily by vaginal swabbing before and during treatment. The monkeys were housed separately in individual cages at the Primate Research Unit, Department of Biology, Faculty of Science, Chulalongkorn University, Bangkok, Thailand. Lighting conditions in the animal room were controlled (12:12 h light to dark cycle). Temperature and humidity fluctuated slightly depending on the season. The monkeys were fed daily with monkey chow (Pokaphan Animal Feed Co., Ltd., Bangkok, Thailand) in the morning (09:00–10:00 h) and were given fresh fruits in the afternoon (14:00–15:00 h). The experimental protocol was approved by the ethics committee in accordance with the guide for the care and use of laboratory animals prepared by the Primate Research Unit, Chulalongkorn University.

Experimental design

The nine aged menopausal monkeys were divided into three groups. The monkeys in each group (n=3) were fed daily with a suspension of PM at doses of 10, 100, or 1,000 mg/individual/day between 08:00–08:30 h. (hereafter abbreviated as PM-10, PM-100, and PM-1,000) The treatment schedule was separated into 3 periods: pre-treatment, treatment, and post-treatment for 30, 90, and 60 days, respectively. During the pre-treatment and post-treatment periods, monkeys were fed with 5 ml of distilled water. Blood samples, 3 ml, were collected from the femoral vein without anesthetization between 08:30–09:30 h every 5 days, then centrifuged 1,700 × g at 4 C, for 20 minutes and stored at –20 C until PTH, estradiol, and calcium were assayed.

P. mirifica suspension preparation

The fresh tuberous roots of PM were sliced, desiccated in a hot air oven at 70 C, and subsequently ground into 100 mesh powder. Then, the powdered stock was kept in a dark desiccator until preparation of the suspension with distilled water. The PM suspension was kept in a dark bottle at 4 C until feeding time

Hormonal analyses

Serum total calcium levels were measured by an atomic absorption spectrophotometer (AAS) according the method of Zettner and Seligson using a Roche/Hitachi system [23]. After extraction with ether, the serum level of estradiol was determined by RIA with ³H-labeled radioligands as described by the established method of the World Health Organization (WHO) [24]. Serum PTH levels was assayed by a PTH-C radioimmunoassay kit (Eiken Chemical Co.Ltd. Bunkyo-ku, Tokyo, Japan). The procedure of the PTH assay and parallel checks

were described in a previous report [25].

Statistical analysis

Serum levels of hormones were expressed as mean ± S.E.M. Analysis of variance (ANOVA) followed by the LSD test was applied to determine the significance of difference among the three periods of the experiment, and among the three groups. Differences were considered significant at $P < 0.05$.

Results

Characteristics of hormonal pattern in aged menopausal monkeys

The menopausal state of the monkeys was confirmed by lower levels of serum estradiol (14.71 ± 1.18 pg/ml) and higher levels of LH (5.85 ± 0.80 ng/ml) compared to normal cyclic monkeys in the early follicular phase of the menstrual cycle in our




Fig. 1. Relationship between basal serum levels of PTH and calcium with estradiol in aged menopausal monkeys.




Fig. 2. Changes in serum PTH, calcium, and estradiol levels during the pre-treatment (A), treatment (B), and post-treatment (C) periods in monkeys treated with PM-10 (n=3). The horizontal bar indicates the treatment period. Stars show significant differences compared to pre-treatment levels ($P < 0.05$).




Fig. 3. Changes in serum PTH, calcium, and estradiol levels during the pre-treatment (A), treatment (B), and post-treatment (C) periods in monkeys treated with PM-100 ($n=3$). The horizontal bar indicates the treatment period. Stars show significant differences compared to pre-treatment levels ($P<0.05$).




Fig. 4. Changes in serum PTH, calcium, and estradiol levels during the pre-treatment (A), treatment (B), and post-treatment (C) periods in monkeys treated with PM-1,000 ($n=3$). The horizontal bar indicates the treatment period. Stars show significant differences compared to pre-treatment levels ($P<0.05$).

colony (27.54 ± 4.31 pg/ml for estradiol and 0.51 ± 0.03 ng/ml for LH, unpublished data). Figure 1 shows the relationship between basal levels of estradiol and PTH as well as calcium. There was a slight positive correlation between the basal levels of calcium and estradiol ($r=0.46$, $P=0.001$), but no correlation between the levels of PTH and estradiol ($r=-0.02$, $P=0.88$).

Changes in serum PTH, calcium, and estradiol levels in monkeys treated with PM

Changes in serum PTH, calcium, and estradiol levels during the pre-treatment, treatment, and post-treatment periods in monkeys treated with PM-10, PM-100, and PM-1,000 are shown in Figs. 2–4. As shown in Fig. 2, monkeys treated with PM-10 showed a trend, but not significant, for the PTH level to become lower on days 40–90 ($0.06 \leq P \leq 0.51$) in the treatment period, than that in the pre-treatment period, except day 80 ($P=0.02$). After the

cessation of PM treatment, the PTH level was quickly returned to the pre-treatment levels. Serum calcium levels decreased significantly on day 75 ($P=0.01$) during the treatment period but gradually returned to the basal levels thereafter. Serum estradiol levels significantly but sporadically decreased (days 30, 55, 65, 70, and 90 during the treatment period; $0.01 < P < 0.047$, and days 5, 15, and 25 during the post-treatment period; $0.04 < P < 0.05$).

As shown in Fig. 3, monkeys treated with PM-100 did not have significantly changed PTH and calcium levels throughout the study period. Estradiol levels decreased significantly at some points during the treatment (days 15, 20, 55, 70, 75, and day 90; $0.03 < P < 0.05$) and post-treatment periods (days 5 and 10; $0.03 < P < 0.05$) compared to the pre-treatment levels.

As shown in Fig. 4, monkeys treated with PM-1,000 showed a significant decrease in PTH levels during the treatment ($0.001 < P < 0.05$) compared to

the pre-treatment levels. PTH levels remained low for the first 15 days of the post-treatment period ($0.01 < P < 0.05$). Calcium levels decreased significantly only in the latter half of treatment period ($0.001 < P \leq 0.03$) and returned to the pre-treatment levels during the early post-treatment period. Estradiol levels were significantly lower than the pre-treatment levels on day 65 ($P=0.03$) of the treatment period and on day 20 ($P=0.01$) of the post-treatment period.

Discussion

Healthy menopausal monkeys have low levels of serum estradiol and there is a positive correlation between estradiol levels and calcium levels in their serum. It has been proposed that changes in estradiol levels influence intestinal calcium absorption and increase serum calcium levels as found in healthy humans [26]. However, we did not find the correlation between estradiol levels and PTH levels because of vary estradiol levels.

Our study is the first to report on the effect of phytoestrogens from the medicinal plant, PM, on altering serum levels of PTH and calcium in estrogen deficient animals. The results clearly demonstrate that aged menopausal monkeys treated with PM had reduced in PTH levels which were followed by a decline in serum calcium levels. The highest dose (PM-1,000) seems to have been more effective for the decrease of PTH and calcium levels than the lowest dose (PM-10). The effect, however, did not depend on dose, because a significant decrease was not observed in the PM-100 group. The reason why there was no effect of PM-100 on serum PTH and calcium levels in this study remains unknown.

Similar to our result, post-menopausal women consuming high isoflavones from a soy diet had lower levels of serum PTH [6]. The decrease of PTH levels was associated with increased BMD in the lumbar spine and Ward's triangle, suggesting that high intake of phytoestrogens may help to improve the state of hyperparathyroidism in postmenopausal women resulting in both lower rates of bone turnover and bone loss [6].

Estrogen administrations have been demonstrated to decrease serum levels of PTH and calcium in postmenopausal women [27, 28]. It has been suggested that estrogen directly inhibits bone

resorption, leading to a decrease in calcium release from the bone into the blood circulation [27, 28]. Estrogen may have a direct action on enhancing intestinal and renal tubular calcium absorption and modulating calcium homeostasis [29]. In addition, an *in vitro* study showed that estrogen receptor (ER) was found in parathyroid cells, and estradiol, treatment caused a decrease in their basal DNA synthesis [30], suggesting that estrogen may have a direct effect on PTH secretion.

We consider that phytoestrogens in *P. mirifica* behave as an estrogen and decrease the PTH levels, since phytoestrogens compete with estradiol to bind to estrogen receptors, which are found in the renal, gastrointestinal tract, and bone [31, 32]. Phytoestrogens may effect these organs, improving calcium absorption, resulting in a secondary decrease in the PTH level. Based on the findings of Wong *et al.* [30] described above, we hypothesize that PM phytoestrogens have a direct action on decreasing PTH secretion from the parathyroid gland.

It is known that the mechanism of PTH in regulating calcium balance is very complex. Normally, it acts directly on the bone and kidney to increase calcium influx into the blood circulation. It also stimulates indirectly calcium absorption by the intestine. The overall effect of PTH is to increase the circulating calcium level [2]. Administration of PTH increased the serum calcium level in patients with hypoparathyroidism [33]. Low levels of serum PTH induced a reduction of serum calcium level in the blood circulation [2]. The results of the present study show that long-term treatment with PM can suppress the serum PTH level, followed by a decrease in the serum calcium level.

Although the long-term treatment of PM led to a decrease in serum calcium, serum calcium levels during the treatment period in all monkey groups (9.91 ± 0.13 mg/dl) stayed in a narrow range and remained within the normal range (10.57 ± 0.22 mg/dl) of aged monkeys. After the cessation of PM treatment, serum calcium levels returned to the pre-treatment level. Calcium is of fundamental importance to all biological activities, and it is also a vital component, not only in the mechanism of hormone secretion, but also in hormone action and is involved in neurotransmission and muscle contraction. For this reason, it is vital that the serum calcium concentration is kept within a narrow range. The fact that aged monkeys treated

with PM for 90 days, did not have greatly lowered serum calcium levels outside their normal range, means that the long-term treatment of PM, which contains phytoestrogens, does not have an adverse effect on calcium homeostasis in the physiological system.

Although our study cannot completely explain the mechanism of PM on the decrease of PTH and calcium levels, at the very least it can be said that the effects on PTH and calcium levels were not caused by endogenous ovarian estradiol but by PM phytoestrogens. This was confirmed by the low estradiol levels seen throughout the study period in all monkey groups. During PM treatment, serum estradiol levels were even lower than those in the pre-treatment period, which is considered to have been caused by a reduction in peripheral conversion of estrone and testosterone to estradiol. Previous reports showed that both genistein and coumestrol reduced conversion of estrone to estradiol [34, 35], and of androstenedione and testosterone to estradiol in human granulosa luteal cells [36].

In summary, the long-term treatment of 1,000 mg/day of PM can decrease the serum levels of PTH and calcium in aged menopausal monkeys. The present study suggests that 1,000 mg/day of PM has a beneficial effect on preservation of calcium content in the bone by reducing PTH secretion. However, to determine the appropriate dose of PM to reduce bone loss in menopausal women additional studies are necessary.

Acknowledgments

This work was supported by The Thailand Research Fund (TRF) contract no. PHD/0014/2544 for the Royal Golden Jubilee Program, (RGJ network) and no. BGJ/15/2544, Chulalongkorn University Research Grant and a Grant-in-Aid for Scientific Research (The 21st Century Center-of-Excellence-Program, E-I) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

References

1. **Pacifici R.** Editorial: cytokines, estrogen and postmenopausal osteoporosis—the second decade. *Endocrinology* 1988; 139: 2659–2661.
2. **Silverberg SJ, Bilezikian JP.** Parathyroid function and responsiveness in osteoporosis. In: Bilezikian JP, Marcus R, Levine MA (eds.), *The Parathyroid Basic and Clinical Concepts*. New York: Raven Press; 1994: 805–812.
3. **McKane WR, Khosla S, Risteli J, Robins SP, Muhs JM, Riggs BL.** Role of estrogen deficiency in pathogenesis of secondary hyperparathyroidism and increased bone resorption in elderly women. *Proc Assoc Am Physicians* 1997; 109: 174–180.
4. **Delmas PD, Stenner D, Wahner HW, Mann KG, Riggs BL.** Increase in serum bone gamma-carboxyglutamic acid protein with aging in women. Implications for the mechanism of age-related bone loss. *J Clin Invest* 1983; 71: 1316–1321.
5. **Ishimi Y, Miyaura C, Ohmura M, Onoe Y, Sato T, Uchiyama Y, Ito M, Wang X, Suda T, Ikegami S.** Selective effects of genistein, a soybean isoflavone, on B-lymphopoiesis and bone loss caused by estrogen deficiency. *Endocrinology* 1999; 140: 1893–1900.
6. **Mei J, Yeung SSC, Kung AWC.** High dietary phytoestrogen intake is associated with higher bone mineral density in postmenopausal but not premenopausal women. *J Clin Endocrinol Metab* 2001; 86: 5217–5221.
7. **Yamori Y, Moriguchi E, Teramoto T, Miura MS, Fukui Y, Honda K, Fukui M, Nara Y, Taira, K, Moriguchi Y.** Soybean isoflavones reduce postmenopausal bone resorption in female Japanese immigrants in Brazil: A Ten-week study. *J Am Coll Nutr* 2002; 21: 560–563.
8. **Blum SC, Heaton SN, Bowman BM, Hegsted M, Miller SC.** Dietary soy protein maintains some indices of bone mineral density and bone formation in aged ovariectomized rats. *J Nutr* 2003; 133: 1244–1249.
9. **Gao YH, Yamaguchi M.** Inhibitory effect of genistein on osteoclast-like cell formation in mouse marrow cultures. *Biochem Pharmacol* 1999; 58: 767–772.
10. **Yamaguchi M, Gao YH.** Inhibitory effect of genistein on bone resorption in tissue culture. *Biochem Pharmacol* 1998; 55: 71–76.
11. **Pope GS, Grundy HM, Jones HEM, Tait SAS.** The estrogenic substance (miroestrol) from the tuberous roots of *Pueraria mirifica*. *J Endocrinol* 1958; 17: 15–16.
12. **Jones HEH, Pope GS.** A study of the action of miroestrol and other oestrogens on the reproductive tract of the immature female mouse. *J Endocrinol* 1960; 20: 229–235.

13. **Chansakaow S, Ishikawa T, Seki H, Sekine K, Okada M, Chaichantipyuth C.** Identification of deoxymiroestrol as the actual rejuvenating principle of "kwao keur" *Pueraria mirifica*. The known miroestrol may be an artifact. *J Nat Prod* 2000; 63: 173–175.
14. **Ingham JL, Tahara S, Dziedzic SZ.** Coumestans from the roots of *Pueraria mirifica*. *Z Naturforsch* 1988; 43c: 5–10.
15. **Ingham JL, Tahara S, Dziedzic SZ.** Minor isoflavones from the roots of *Pueraria mirifica*. *Z Naturforsch* 1989; 44c: 724–726.
16. **Smitasiri Y, Junyatum U, Songjitsawad A, Sripromma P, Trisisilp S, Anuntalabhochai S.** Postcoital antifertility effects of *Pueraria mirifica* in rats. *J Sci Fac CMU* 1986; 13: 19–28.
17. **Smitasiri Y, Pangjit S, Anuntalabhochai S.** Inhibition of lactation in lactating rats with *Pueraria mirifica* compared with estrogen. *J Sci Fac CMU* 1989; 16: 7–11.
18. **Trisomboon H, Malaivijitnond S, Watanabe G, Taya K.** Estrogenic effects of *Pueraria mirifica* on the menstrual cycle and hormones related ovarian functions in cyclic female cynomolgus monkeys. *J Pharmacol Sci* 2004; 94: 51–54.
19. **Trisomboon H, Malaivijitnond S, Taya K, Watanabe G, Suzuki J.** Potential role of *Pueraria mirifica* on reproductive hormones in aged female cynomolgus monkeys. In: 4th Intercongress Symposium of the Asia and Oceania Society for Comparative Endocrinology; 2002; 4: 0–19.
20. **Muangman V, Cherdshewasart W.** Clinical Trial of the phytoestrogen-rich herb, *Pueraria mirifica* as a crude drug in the treatment of symptoms in menopausal women. *Siriraj Hosp Gaz* 2001; 53: 300–309.
21. **Malaivijitnond S, Varavudhi P.** Evidence for morphine-induced galactorrhea in male cynomolgus monkeys. *J Med Primatol* 1998; 27: 1–9.
22. **Krajewski SJ, Abel TW, Voytko ML, Rance NE.** Ovarian steroids differentially modulate the gene expression of gonadotropin-releasing hormone neuronal subtypes in the ovariectomized cynomolgus monkey. *J Clin Endocrinol Metab* 2003; 88: 665–662.
23. **Zettmer A, Seligson D.** Application of atomic absorption spectrophotometry in the determination of calcium in serum. *Clin Chem* 1964; 10: 869–890.
24. **Sufi SB, Donaldson A, Jeffcoate SL.** WHO matched reagent program method manual. In: WHO collaborating center for immunoassay; 1983; London.
25. **Malaivijitnond S, Trisomboon H, Cherdshewasart W, Juri S, Yuzuru H, Kikuchi Y, Takenaka O.** Changes of aged related factors in various age of cynomolgus monkeys and after treated with *Pueraria mirifica* phytoestrogens. In: COE International Symposium Development and Aging of Primates; 2000; 68.
26. **Fujusawa Y, Kida K, Matsuda H.** Role of change in vitamin D metabolism with age in calcium and phosphorus metabolism in normal human subjects. *J Clin Endocrinol Metab* 1984: 7119–7226.
27. **Stock JL, Coderre JA, Mallette LE.** Effects of a short course of estrogen on mineral metabolism in postmenopausal women. *J Clin Endocrinol Metab* 1985; 61: 596–600.
28. **Khosla S, Atkinson EJ, Melton LJ, Riggs BL.** Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population-based study. *J Clin Endocrinol Metab* 1997; 82: 1522–1527.
29. **Vincent A, Riggs BL, Atkinson EJ, Oberg AL, Khosla S.** Effect of estrogen replacement therapy on parathyroid hormone secretion in elderly postmenopausal women. *Menopause* 2003; 10: 165–171.
30. **Wong C, Lai T, Hilly JM, Stewart CEH, Farndon JR.** Selective estrogen receptor modulators inhibit the effects of insulin-like growth factors in hyperparathyroidism. *Surgery* 2002; 132: 998–1007.
31. **Onoe Y, Miyaura C, Ohta H, Nozawa S, Suda T.** Expression of estrogen receptor β in rat bone. *Endocrinology* 1997; 138: 4509–4512.
32. **Gustafsson J.** Estrogen receptor β -a new dimension in estrogen mechanism of action. *J Endocrinol* 1999; 163: 379–383.
33. **Winner KK, Yanovski JA, Sarani B, Cutler GB.** A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1–34 in treatment of hypoparathyroidism. *J Clin Endocrinol Metab* 1998; 83: 3480–3486.
34. **Makela S, Poutanen M, Lehtimaki J, Kostian ML, Santti R, Vihko R.** Estrogen-specific 17 beta-hydroxysteroid oxidoreductase type 1 (E.C. 1.1.1.62) as a possible target for the action of phytoestrogens. *Proc Soc Exp Biol Med* 1995; 208: 51–59.
35. **Whitehead SA, Cross JE, Burden C, Lacey M.** Acute and chronic effects of genistein, tyrphostin and lavendustin A on steroid synthesis in luteinized human granulosa cells. *Hum Reprod* 2002; 17: 589–594.

Malignant NK/T-Cell Lymphoma Associated with Simian Epstein-Barr Virus Infection in a Japanese Macaque (*Macaca fuscata*)

Juri SUZUKI¹⁾, Shunji GOTO¹⁾, Akino KATO¹⁾, Chihiro HASHIMOTO¹⁾, Norikatsu MIWA¹⁾, Satomi TAKAO²⁾, Takafumi ISHIDA²⁾, Ayumi FUKUOKA³⁾, Hiroyuki NAKAYAMA³⁾, Kunio DOI³⁾, and Koichi ISOWA⁴⁾

¹⁾Primate Research Institute, Kyoto University, Inuyama, Aichi 484-8506, ²⁾Graduate School of Science, University of Tokyo, Bunkyo, Tokyo 113-0033, ³⁾Graduate School of Agricultural and Life Sciences, University of Tokyo, Bunkyo, Tokyo 113-8657, and ⁴⁾Japan Bioscience Center Co., Ltd., Kaizu, Gifu 503-0628, Japan

Abstract: A case of spontaneous malignant lymphoma in a Japanese macaque (*Macaca fuscata*) was pathologically, etiologically and virologically studied. Nasal cavity was involved in the neoplastic lesions in addition to lymphoid and visceral tissues. Histopathological analyses revealed the presence of neoplastic cells classified into histiocytic Hodgkin-like cells and Reed-Sternberg-like cells. Histiocytic Hodgkin-like cells were CD16+ and CD20+, and the CD16+ cells were also positive for simian Epstein-Barr virus (sEBV)-encoded early RNA transcripts. RS-like cells were negative for CD3, CD16 and CD20. Antibodies to early antigen of sEBV were detected, while antibodies to simian T-cell leukemia virus-1 were negative. The case may correspond to EBV-associated nasal type NK/T-cell lymphoma in humans rather than Hodgkin lymphoma.

Key words: Japanese macaques, malignant lymphoma, simian Epstein-Barr virus

Malignant lymphomas are common neoplasms in non-human primates [1, 9, 30] as in humans. Classification of lymphomas in non-human primates, however, is based only on the morphological features. In humans, Hodgkin lymphoma is distinguished from non-Hodgkin lymphoma by the presence of Hodgkin cells (histiocytic neoplastic cells with noticeable nucleus) and/or multinucleated Reed-Sternberg (RS) cells [2] that are derived from B cells in the germinal center, and moreover by various neoplastic cell mark-

ers [7, 24]. Analyses of CD markers also help us to classify non-Hodgkin lymphoma in non-human primates and provide more information about the lymphomagenesis [3, 21, 22]. There has been so far only one report on lymphoma with CD marker analyses for the Japanese macaque (*Macaca fuscata*) [31]. However, histological and etiological information were lacking from that report and a systematic study on primate malignant lymphoma has been awaited.

Certain groups of viruses are tightly associated with

(Received 27 April, 2004 / Accepted 25 August, 2004)

Address corresponding: J. Suzuki, Center for Human Evolution Modeling Research, Primate Research Institute, Kyoto University, Inuyama, Aichi 484-8506, Japan

and participate in lymphomagenesis in non-human primates as well as in humans. Epstein-Barr virus (EBV) classified as a lymphocrypt gamma herpesvirus is an etiological agent of lymphoproliferative disorders including Burkitt's lymphoma and infectious mononucleosis in humans [26, 33]. Recent studies on malignant lymphoma have revealed that EBV contributes to the development of Hodgkin and non-Hodgkin lymphoma including T-cell lymphomas such as NK/T-cell lymphoma [4, 5]. Virus isolates relevant to human EBV have been found in non-human primates and are called simian EBV (sEBV) [18]. The sEBV is well known to play an important role in oncogenesis in macaques [16, 25], and 98% of Japanese macaques were seropositive for anti-sEBV viral capsid antigen (sEBV VCA) [11, 12]. One of the primate T-lymphotropic retroviruses, simian T-cell leukemia virus (STLV)-1, has the potential to develop T-cell lymphoma in baboons (*Papio spp.*) [10] and African green monkeys (*Cercopithecus aethiops*) [17], and about 30% of Japanese macaques have been reported to be seropositive for STLV-1 [13, 14].

Recently, a Japanese macaque in our colony was found to have developed a malignant lymphoma and subsequently died. We here report the histopathological, virological and etiological data of the case.

The macaque was born and reared at the Primate Research Institute of Kyoto University. The rearing conditions were described in detail in our previous report [28]. The animal was a male Japanese macaque aged 4.6 years (yrs) and belonged to the Arashiyama troop. Autopsy was performed immediately after the death. Tissues with gross lesions were fixed in 10% formalin solution, embedded in paraffin, sectioned at 5 μm , and stained with hematoxylin and eosin (HE) for histopathological observation.

Immunostaining was performed on paraffin-embedded sections of tissues using antibodies to human CD3 (PS1, Nichirei, Japan) for T-cells, CD16 (NCL-CD16, Novo castra, UK) for NK-cells and CD20 (L26, Nichirei, Japan) for B-cells, which had been confirmed cross-reactive with Japanese macaque's lymphoid antigens on paraffin-embedded sections. Positive signals were visualized by using a Dako LSAB2/HRP kit (DakoCytomation, Japan).

To confirm the presence of sEBV in tumor cells, *in situ* hybridization was performed on sections of tissues

using fluorescein-conjugated oligonucleotides (5'-ATCTCCTCCCCAGCATAACCGCTAGGGCAG-3' and 5'-ACCCCCCTCTGTCCGTAACCTC-TAGGCTAG-3') complementary to the portions of the sEBV-encoded early RNA transcripts (sEBERs) that are actively transcribed in latently infected cells. Sections of tissues, axillary and inguinal lymph nodes, of a normal Japanese macaque were used as a control. Signals for sEBERs were visualized by Universal RNA ISH and a DIG-AP detection kit (Nichirei, Japan).

Infection with STLV-1 was monitored by the detection of specific antibody to STLV-1 with an indirect immunofluorescence method. The procedure has been described previously [13]. As for the sEBV infection status, the presence of anti-sEBV VCA antibody and anti-sEBV early antigen (sEA) antibody were used as markers for the sEBV infection and the possible presence of sEBV associated cell proliferative diseases, respectively [22]. P3HR-1 cells [8] treated with 4 mM n-butyric acid (Wako Chem., Japan) and 20 ng/ml 12-tetradecanoylphorbol-13-acetate (TPA) (Sigma, USA) for 48 h, and Raji cells [23] treated with 20 ng/ml TPA for 5 days were fixed with acetone and used as target antigens of sEBV VCA and sEA, respectively. Fluorescein isothiocyanate-conjugated goat antibody to human immunoglobulins (Medical & Biological Laboratories, Japan) was used to visualize a positive reaction under a fluorescence microscope. The procedure for the detection of plasma antibodies to sEBV VCA and sEA has been described in detail previously [11].

At 3.8 yrs of age, lameness of the left hind limb, high body temperature (39.3°C), increase in white blood cell count (25,600/mm³) and high concentration of plasma C-reactive protein (CRP) (2.6 mg/dl) were observed. A mass in the left nasal cavity with hemorrhage and rhinorrhea, and swelling of the axial lymph nodes were found at 4.6 yrs of age. Severe anemia (RBC 289 $\times 10^4$ /mm³, hemoglobin 6.2 g/dl, and hematocrit 22.5%), low platelet count (10 $\times 10^4$ /mm³) and high CRP (3.3 mg/dl) and high alkaline phosphatase (1,537 unit/litter) levels were documented before death at the age of 4.6 yrs. A hemogram was not available in the present case.

Gross lesions were characterized by systemic swelling of various lymph nodes (30–70 mm in diameter), a neoplastic mass in the nasal cavity (30 \times 15 \times 15 mm) and splenomegaly (1,250 \times 850 \times 300 mm).

Histopathological findings of the lymph nodes in-




Fig. 1. Neoplastic lesion of the Japanese macaque. Bar = 10 μ m. A: HE staining for the mediastinal lymph node. Hodgkin-like histiocytic and RS-like cells are observed. Mononuclear or binuclear RS-like cells are seen in the upper and the central parts. B: CD16+ neoplastic cells in the nasal lesion. Immunohistochemistry C: CD20+ neoplastic cells in the iliac lymph node. Immunohistochemistry. D: sEBER-positive neoplastic cells in the nasal lesion. *In situ* hybridization.

cluding axillary, mediastinal, gastric and iliac were as follows (Fig. 1A). Neoplastic histiocytic cells were proliferated diffusely. Multinucleated RS-like cells having eosinophilic and foamy cytoplasm with polymorphic or kidney-shaped nuclei were scattered in the lesion. Mirror-image in RS-like cells was often observed. Non-neoplastic lymphocytes were diffusely infiltrated into the lesion. Necrosis and fibrosis were apparent in part of the lesion. The lung, liver, spleen and the tumor mass in the left nasal cavity exhibited similar histopathological findings to those in lymph nodes. In the liver, neoplastic cells and non-neoplastic lymphocytes proliferated mainly at the Glisson's sheath.

The histiocytic neoplastic cells were positive for CD16 but negative for CD3 in any organs examined, while CD20-positive histiocytic neoplastic cells were recognized only in the iliac lymph node (Figs. 1B and 1C). RS-like cells were negative for CD3, CD16 and CD20.

Anti-STLV-I antibody was not detected in the case.

The titers of anti-sVCA antibody were 1: 160 at 4.6 yrs. Simultaneously anti-sEA antibody was 1: 40. *In situ* hybridization revealed the expression of sEBER in the CD16-positive histiocytic neoplastic cells but not in the RS-like cells of all tissues examined (Table 1, Figs 1B and 1D).

Expression of sEBERs in the neoplastic cells and the concurrent presence of anti-sEA antibody suggest the important role(s) of sEBV in the lymphomagenesis in the present case. Infection of EBV in humans and sEBV in macaques is widely disseminated and causes B-cell malignancies such as Burkitt-type lymphoma. In addition, their frequent involvement even in Hodgkin lymphoma and the non B-cell lymphomas such as NK/T-cell lymphoma has been pointed out [4, 5].

Histopathological observations for the present case revealed that the neoplastic cells were composed of two types. One was round-shaped histiocytic cells (Hodgkin-like cells) with poor to rich cytoplasm and a dark or pale-stained nucleus, and the other was multi-

Table 1. Immunophenotype and sEBV related features of neoplastic cells

	Antibody to			Neoplastic cells* positive for			
	STLV-1	sVCA	sEA	sEBER	CD3	CD16	CD20
	-	1:160	1:40				
Tumor of nasal cavity				+	-	+**	-
Iliac lymph node				+	-	+	+
Liver				+	-	+	-
Spleen				+	-	+	-

*: RS-like cells were negative for all those markers. **: CD16-positive cells were identical to sEBERs-positive cells.

nuclear RS-like cells which are the typical cells of Hodgkin lymphoma in humans [7, 24] and some lymphomas of non-human primates [6, 20]. The ratio of the two cell types varied among the organs where the lesions were observed. Although morphological similarity to human Hodgkin lymphoma was observed in the present case, the majority of neoplastic cells were histiocytic cells with few inflammatory cells in the lesion. Hodgkin lymphoma in humans is characterized by a few RS cells with an inflammatory cell background [15]. These differences suggest that the present case is not comparable with Hodgkin lymphoma in humans.

One of the human non-Hodgkin lymphomas associated with EBV-infection, nasal type NK/T-cell lymphoma [15], manifests nasal involvement of the lesion, prolonged fever, anemia, body weight loss and a high alkaline phosphatase level. Histopathology of nasal type NK/T-cell human lymphoma is characterized by the proliferation of pleomorphic lymphoid cells with the occasional presence of Hodgkin/RS-like cells [27]. The phenotype of the lymphoma cells in the nasal lesion is EBER+, CD2+, CD3-, CD4+, CD8+, CD19-, CD30- and CD56+ [19, 29].

The present macaque case showed nasal involvement and a high alkaline phosphatase level and suffered from severe anemia. Phenotypes of the neoplastic histiocytic cells of the case were sEBER+, CD3-, CD16+ and CD20- in the nasal lesion, and sEBER+, CD3-, CD16+ and CD20+ in the iliac lymph node. For the detection of NK-cells, an antibody to human CD16 was used instead of anti-human CD56 antibody, since the reactivity of a selected anti-human CD56 antibody to monkey cells has not been confirmed. CD16 is also used as another marker to confirm this type of lymphoma [15, 19]. The appearance of CD20+ neoplastic

NK/T-cells in the iliac lymph node corresponded to a previous observation in human T-cell lymphoma with an aberrant expression of CD20 and CD79a (both are B-cell markers) [32].

These comparable symptoms and laboratory findings suggest that the present case was a monkey type of nasal NK/T-cell lymphoma rather than Hodgkin lymphoma. The present case, in particular, is highly significant because the number of EBV-associated NK/T-cell lymphoma cases are increasing in humans. Further molecular analyses of the case may establish macaques as an animal model for EBV-associated T-cell or NK/T-cell lymphoma.

Acknowledgments

We are grateful to Prof. W. Mitarnun, Department of Pathology, Faculty of Medicine, Prince of Songkla University, Hat-Yai, Thailand, for his valuable advice. This study was supported in part by the grant in aid for scientific research, MEXT Japan.

References

1. Beniashvili, D.A. 1989. *J. Med. Primatol.* 18: 423-437.
2. Damjanov, I. and Linder, J. 2001. *Pathology: A Color Atlas*. 1st Japanese ed., Medical Sciences International, Ltd., Tokyo (in Japanese).
3. Feichtinger, H., Kaaya, E.E., Li, S.-L., Putkonen, P., Grünewald, K., Weyrer, K., Offner, F., Biberfeld, G., and Biberfeld, P. 1992. *Verh. Dtsch. Ges. Path.* 76: 189-193.
4. Flavell, K.J. and Murray, P.G. 2000. *J. Clin. Pathol.: Mol. Pathol.* 53: 262-269.
5. Gaal, K., Sun, N.C.J., Herneandez, A.M., and Arber, D.A. 2000. *Am. J. Surg. Pathol.* 24: 1511-1517.
6. Gleiser, C.A., Carey, K.D., and Heberling, R.L. 1984. *Lab. Anim. Sci.* 34: 286-289.
7. Herling, M., Rassidakis, G.Z., Medeiros, L.J., Vassilakopoulos, T.P., Kliche, K.-O., Nadali, G., Viviani,

- S., Bonfante, V., Giardini, R., Chilosi, M., Kittas, C., Gianni, A.M., Bonadonna, G., Pizzolo, G., Pangalis, G.A., Cabanillas, F., and Sarris, A.H. 2003. *Clin. Cancer Res.* 9: 2114–2120.
8. Hinuma, Y., Konn, M., Yamaguchi, J., Wudarski, D.J., Blakeslee, J.R., and Grace, J.T. 1967. *J. Virol.* 1: 1045–1051.
9. Holmberg, C.A., Osburn, B.I., Terrell, T.G., and Manning, J.S. 1978. *Am. J. Vet. Res.* 39: 469–472.
10. Hubbard, G.B., Moné, J.P., Allan, J.S., Davis, I.K.J., Leland, M.M., Banks, P.M., and Smir, B. 1993. *Lab. Anim. Sci.* 43: 301–309.
11. Ishida, T., Suzuki, J., and Yamamoto, K. 1993. *Folia Primatol.* 61: 228–233.
12. Ishida, T. and Yamamoto, K. 1987. *J. Med. Primatol.* 16: 359–371.
13. Ishida, T., Yamamoto, K., Kaneko, R., Tokita, E., and Hinuma, Y. 1983. *Microbiol. Immunol.* 27: 297–301.
14. Ishikawa, K., Fukasawa, M., Tsujimoto, H., Else, J.G., Isahakia, M., Ubhi, N. K., Ishida, T., Takenaka, O., Kawamoto, Y., Shotake, T., Ohsawa, H., Ivanoff, B., Cooper, R. W., Frost, E., Grant, F.C., Spriatna, Y., Sutarman, Abe, K., Yamamoto, K., and Hayami, M. 1987. *Int. J. Cancer* 40: 233–239.
15. Jaffe, E.S., Harris, N.E., Stein, H., and Vardiman, J.W. 2001. World Health Organization Classification of Tumours. Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research of Cancer Press, Lyon, France.
16. Jayo, M.J., Jayo, J.M., Jerome, C.P., Krugner-Higby, L., and Reynolds, G.D. 1988. *Lab. Anim. Sci.* 38: 722–726.
17. Jayo, M.J., Laber-Laird, K., Bullock, B.C., Tulli, H.M., and Reynolds, G.M. 1990. *Lab. Anim. Sci.* 40: 37–41.
18. Levy, J.A., Levy, S.B., Hirshaut, Y., Kafuko, G., and Prince, A. 1971. *Nature* 233: 559–560.
19. Mitarnun, W., Saechan, V., Pradutkanchana, J., Suwivat, S., Takao, S., and Ishida, T. 2003. *J. Med. Assoc. Thai.* 86: 816–827.
20. Morita, M. 1974. *Primates* 15: 47–53.
21. Mätz-Rensing, K., Pingel, S., Hanning, H., Bodemer, W., Hunsmann, G., Kuhn, E.-M., Tiemann, M., and Kaup, F.-J. 1999. *J. Med. Primatol.* 28: 318–328.
22. Paramastri, Y.A., Wallace, J.M., Salleng, K.J., Wilkinson, L.M., Malarkey, D.E., and Cline, J. M. 2002. *Vet. Pathol.* 39: 399–402.
23. Purvertaft, R.J.V. 1964. *The Lancet* I: 238–240.
24. Rassidakis, G.Z., Medeiros, L.J., Viviani, S., Bonfante, V., Nadali, G.-P., Vassilakopoulos, T.P., Mesina, O., Herling, M., Angelopolou, M.K., Giardini, R., Chilosi, M., Kittas, C., McLaughlin, P., Rodriguez, M.A., Romaguera, J., Bonadonna, G., Gianni, A.M., Pizzolo, G., Pangalis, G.A., Cabanillas, F., and Sarris, A.H. 2002. *J. Clin. Oncol.* 20: 1278–1287.
25. Stowell, R.E., Smith, E.K., España, C., and Nelson, V.G. 1971. *Lab. Invest.* 25: 476–479.
26. Straus, S.E., Cohen, J.I., Tosato, G., and Meier, J. 1993. *Ann. Intern. Med.* 118: 45–58.
27. Suchi, T. 2000. New atlas of malignant lymphoma. Bunkodo, Tokyo.
28. Suzuki, J., Miwa, N., Kumazaki, K., Abe, M., Kamanaka, Y., Matsubayashi, N., Gotoh, S., and Matsubayashi, K. 2001. *J. Vet. Med. Sci.* 63: 361–366.
29. Tao, Q., Ho, F.C., Loke, S.L., and Srivastava, G. 1995. *Int. J. Cancer* 60: 315–320.
30. Terrell, T.G., Gribble, D.H., and Osburn, B.I. 1980. *J. Natl. Cancer Inst.* 64: 561–568.
31. Yanai, T., Sakai, H., Goto, S., Murata, K., and Masegi, T. 2002. *Jpn. J. Zoo Wildl. Med.* 7: 45–51.
32. Yao, X., Teruya-Feldstein, J., Raffeld, M., Sorbara, L., and Jaffe, E.S. 2001. *Mod. Pathol.* 14: 105–110.
33. Zur Hausen, H., Schulte-Holthausen, H., Klein, G., Henle, W., Henle, G., Clifford, P., and Stantesson, L. 1970. *Nature* 228: 1056–1058.

Yuzuru Hamada · Juri Suzuki · Satoshi Ohkura
Seiji Hayakawa

Changes in testicular and nipple volume related to age and seasonality in Japanese macaques (*Macaca fuscata*), especially in the pre- and post-pubertal periods

Received: 10 September 2003 / Accepted: 21 April 2004 / Published online: 30 September 2004
© Japan Monkey Centre and Springer-Verlag 2004

Abstract We investigated, longitudinally and cross-sectionally, age and seasonal change in both the testis and nipple volume of Japanese macaques (*Macaca fuscata*) in relation to concentration profiles of gonadal steroids: testosterone (T) in males and progesterone (P) in females. Testicular volume (TV) and nipple volume (NV) showed rapid growth at puberty, 4.5 and 3.5 years of age in males and females, respectively, but in both sexes there were precocious individuals. The testis as a whole matures at about 10 years of age. TV change is closely related to T concentration profile. The pattern of TV change is composed of maturation and seasonal effects, with individual variation evident mainly in the latter. Some individuals show a simple pattern consisting of one peak in the breeding season (from summer to winter) and one trough in the non-breeding season. Other individuals exhibit a more complicated pattern composed of two or more peaks and troughs before and during the breeding season. The nipple matures at about 7 years but it is difficult to determine the exact maturational age as there are many confounding factors relating to NV. NV shows seasonal fluctuations similar to that of TV. Many animals have periods of substantial growth whereas others do not. The NV in adults from 10 to 25 years does not appear to change much with age, but animals older than 25 years of age have significantly

smaller nipples. Seasonal fluctuation in NV mirrors that of the P level. Considered to be controlled by estrogen and P, the NV is a good indicator of the physiological status of reproduction, with its peak about 2 weeks earlier than that of P, that is, at the mid-follicular phase. NV and P level show a similar pattern in pregnancy: from conception, indicated by a P peak, NV and P concentration first decrease, then they increase until peri-parturition and slowly decrease again until the next breeding season.

Keywords Testis · Nipple · Puberty · Japanese macaques · Seasonality

Introduction

Japanese macaques (*Macaca fuscata*) inhabit the Japan Islands, where a temperate climate prevails and four seasons are clearly demarcated. They show seasonality not only in body weight (Hazama 1964; Suzuki et al. 2000) and nutritional status (Hamada et al. 2003), but also in reproduction (Nozaki 1991). The breeding season is from autumn to winter (from September to February with a peak in November; Nozaki 1994), and the delivery season is from spring to early summer (from March to August with a peak in May; Nozaki 1994). Seasonality in the reproduction of Japanese macaques is predominantly controlled by day length, temperature, and internal calendar (Nozaki 1991). Similar seasonality has been reported in bonnet macaques (Glick 1979). Due to changes in their nutritional status or environmental conditions, female Japanese macaques are reported to experience their menstrual cycle in the non-breeding season (Mori et al. 1997). External genital organs change in size and/or color depending on the season: in males, the testis becomes larger in the breeding season (Nigi et al. 1980) and the skin on the scrotum, inguinal, peri-anal area, and caudal aspects of the thigh become reddish; in females,

Y. Hamada (✉) · S. Hayakawa
Morphology Section, Primate Research Institute,
Kyoto University, 41 Kanrin, Inuyama 484-8506,
Japan
E-mail: hamada@pri.kyoto-u.ac.jp
Tel.: +81-568-630521
Fax: +81-568-615775

J. Suzuki
Center for Human Evolution Modeling Research,
Primate Research Institute, Kyoto University,
Inuyama, Japan

S. Ohkura
Laboratory of Neuro-endocrinology,
National Institute of Agrobiological Sciences,
Tsukuba, Japan

the so-called "sexual skin" turns reddish and swells; and in both sexes the facial skin reddens.

Sexually dimorphic traits and their development in primates have attracted much attention (Dixson 1998), especially those in humans (Tanner 1962; Malina and Bouchard 1991). The reproduction-related characters mentioned above, comparable to the secondary sexual characters of humans, develop rapidly with the onset of puberty at about 3.5 years in females and 4.5 years in males (Hamada et al. 1999). In humans, facial, axillary, and pubic hair, breast development, testicular development, and voice changes (Tanner 1962) first occur in the adolescent period and rapidly develop. Some of these characters are also found in Japanese macaques, for example, testicular and musculoskeletal development in males or body proportion changes such as fat accumulation in females. Although the Japanese macaque differs markedly from humans in its strict seasonality in reproduction, it appears that the most striking difference is that women show no morphological changes associated with the menstrual cycle. Knowledge about what and how body part(s) change with age and reproductive maturity may shed light on the evolution of the reproductive system, especially as it relates to social structure. In view of this, the morphological changes associated with the reproductive state in Japanese macaques are of interest.

The purpose of this study was to examine age changes, seasonality, and changes in the physiological activity of reproduction in testis and nipple size (volume) in Japanese macaques. Although we have already preliminarily reported on size (Hamada et al. 1999), we extend analyses here with additional data to examine the relationship of changes in testis and nipple volume with the secretion of reproductive hormones, testosterone (T) for males and progesterone (P) for female. The testis produces sperm and secretes steroid hormones and its volume is considered to reflect the state of these functions (Nigi et al. 1980). Although there are some studies on testicular size variation in macaques (Sade 1964; Glick 1979; Nigi et al. 1980; Matsubayashi and Mochizuki 1982; Matsubayashi and Enomoto 1983; Hamada et al. 1996), the details of seasonal change and individual variation in testicular development have not been examined. The nipple appears to change due to growth, sexual maturation, aging, seasonality, and reproductive physiology (menstrual cycle and pregnancy) as mediated by several hormones and lactation. However, although the nipple has been studied from the perspective of behavior (nipple preference, e.g. Tanaka 1989), size variations have not been studied, except by Terasawa et al. (1983), who analyzed nipple size in rhesus macaques (*M. mulatta*) in the peri-pubertal period.

Methods

We adhered strictly to the "Guide for the Care and Use of Laboratory Primates" of the Primate Research

Institute (2003), Kyoto University. Our research protocol was approved by the Animal Welfare and Animal Care Committee.

Subjects for longitudinal observation

We followed the growth and development of 15 subject macaques (5 males and 10 females) from the late juvenile (2 or 3 years) to the late adolescent (7 years) phase. Table 1 lists the dates of birth, periods of study, and numbers of observations. Although some females gave birth, almost all babies were separated from the mother at birth. The period of observation differed with the individual. Five macaques born in the same year were reared in the same group cage, composed of an outdoor (4×6×2.2 m, width × length × height) and an indoor enclosure (3.5×4×2.5 m). Monkey chow was the main food and supplements such as sweet potato or cabbage were given twice a week. The total caloric value of food was determined according to body weight and nutritional status, and water was accessible ad libitum. Somatometrical data were collected every 2 weeks. Subjects were anesthetized with a 2:1 mixture of ketamine hydrochloride (Ketalar 50, Sankyo Co., Ltd., 5 mg/kg body weight) and xyladine (Selactar 2%, Bayer Co. Ltd., 1 mg/kg body weight). Blood was collected by venipuncture every week. Somatometry and blood sampling were made from 11 a.m. after the subjects had fasted overnight.

Subjects of cross-sectional observation

Table 2 lists numbers of cross-sectional data by age and sex. We included longitudinal data points in this tabulation. Subject monkeys other than the longitudinal

Table 1 Subject macaques for the longitudinal measurements

No.	Date of birth	Age during study (years)	Number of observations
Male			
1412	1 June 1992	2.88–6.83	107
1428	25 May 1992	2.90–6.85	106
1439	5 June 1992	2.87–6.82	102
1459	12 March 1993	3.10–7.05	91
1470	5 May 1993	2.95–6.90	91
Total			497
Female			
1433	2 June 1992	4.28–6.83	63
1447	23 June 1992	4.14–6.77	62
1458	31 March 1993	3.47–7.00	81
1460	27 March 1993	3.48–7.01	81
1469	30 April 1993	3.39–6.92	82
1720	2 May 1998	1.95–5.10	68
1729	28 May 1998	1.88–5.02	74
1736	29 May 1998	1.88–5.02	72
1743	9 June 1998	1.85–4.99	73
1744	10 June 1998	1.84–4.99	73
Total			729

Table 2 Number of measurements with age and sex: cross-sectional data

Age (years)	Male	Female	Total
0	3		3
1	9	24	33
2	24	121	145
3	150	123	273
4	137	169	306
5	131	134	265
6	107	104	211
7	10	12	22
8	6	10	16
9–10	6	14	20
11–15	19	24	43
15–20	12	25	37
20–25	12	31	43
25–		14	14
Total	626	805	1,431

subjects were reared in open enclosures of about 800 m². During the annual health inspections, which were carried out in autumn, we collected somatometric data and blood samples. We also added data collected arbitrarily in other seasons.

Somatometry

The length (or height, L in millimeters) and width (or diameter, W in millimeters) of the right testis and nipple were measured to the nearest millimeter with a sliding caliper. Assuming an ellipsoid shape for the testis and a cylindrical column for the nipple, we calculated their volumes as follows: testicular volume (TV, milliliters) = $W^2 \times L \times \pi/6,000$, in which π stands for the circular constant (Marson et al. 1991), and nipple volume (NV, milliliters) = $W^2 \times L \times \pi/4,000$.

Measurement of the concentration of gonadal steroid hormones

We measured the plasma concentration of gonadal steroid hormones, T for males and P for females, to monitor the physiological states of reproduction. In humans, the T level varies within a day with its peak and trough concentrations found in the morning and evening, respectively (Felig et al. 1995). We followed the recommendation that blood be collected at the same time each day (Felig et al. 1995) and sampled animals between 11:00 and 11:30 a.m.

We analyzed the concentration profile of P in the luteal phase to determine the ovulatory menstrual cycle (Nozaki 1991). Although puberty is often determined by menarche, the first menstrual bleeding, as subjects were reared in group cages, that method was not applicable. Reproductive maturation can also be determined by ovulation but the determination of this by direct observation of the ovary requires invasive surgery and anesthesia (Terasawa et al. 1983). The menstrual cycle is often

depicted by changes in the concentrations of serum E2 (17β -estradiol), luteinizing hormone (LH), follicle stimulating hormone (FSH), and P. Thus, one of these hormones can represent the cycle in cases where reproductive cycles occur regularly. Although estrogen is known to stimulate breast development at puberty in girls (Mastroianni and Coutifaris 1990), and the development of nipple size in rhesus monkeys is controlled by E2 (Terasawa et al. 1983), estrogen is secreted in a pulse-like surge and high levels occur for only 48 h during mid-cycle (Johnson and Everitt 1995), so frequent sampling is necessary. The secretion patterns of LH and FSH are similarly pulse-like. The period of secretion of P, however, continues for much longer and P of higher than 1 ng/ml is secreted for more than 1 week (in rhesus macaques, Knobil and Hotchkiss 1988; in Japanese macaques, Nozaki 1991). The concentration of P also indicates the maturational status of the ovary because P is secreted directly from here. Therefore, P was regarded as a more appropriate indicator for the present study in which blood samples were collected weekly. Concentrations of plasma T and P were measured with standard radioimmunoassay kits (for details see Suzuki et al. 2000).

Statistical analyses


We examined the age change (maturation) and seasonality of TV and NV, and hormonal profiles, mainly graphically but also with basic statistics using Excel (Microsoft) and S-Plus 4 (MathSoft). We occasionally smoothed graphs using the loess.smooth function (S-Plus 4, MathSoft). Age was expressed to the order of 0.01 years for analyses, and age and calendar month were used to examine seasonal influences. As the birth dates of subject monkeys were in spring, (range from 12 March to 23 June, average 14 May, see Table 1), age and calendar month and age in years are interchangeable (e.g. the age in years for November at 4 years is about 4.5 years old).

Results

Age change and seasonality in testicular volume (TV)

All cross-sectional data on TV were plotted against age (Fig. 1). TV started its rapid increase at puberty, at about 4.5 years, and matured when the individual became an "adult" at 7 years on average, but there was variation with locality (Nigi et al. 1980; Hamada et al. 1986). Although the variation was considerable after puberty, the maturation pattern of the testis is well depicted by the diagram. In adolescence, considerable seasonal fluctuation was observed. For adults (≥ 7 years), the median is 42.2 ml, and TV for the 10th and 90th percentiles was 23.9 and 65.8 ml, respectively (Fig. 1a). In the range of TV up to 7 years of age, the maximum was close to the 90th percentile of adults, but the mini-

Fig. 1a, b Plots of testicular volume (TV) against age in Japanese macaques. **a** In the adult period, 7–25 years, the median (line and diamonds at both ends), 10th and 90th percentiles (dotted lines and triangle at both ends) are superimposed on the diagram. **b** Detail from 2.5 to 7.0 years of age. Smoothed curves connecting peaks and troughs are superimposed



num (baseline) was smaller than the 10th percentile of adults (Fig. 1b). Therefore, the testis did not appear fully mature at 7 years but it did by about 10 years of age. The oldest monkeys from which we could collect TV measurements were 24 years but we did not note any significant change of TV with age in adults.

Figure 1b shows the details of TV change from the late juvenile to the adolescent period, that is, 3–7 years. TV increased gradually from 3.0 to 4.2 years of age. Although some individuals exhibited a much greater TV than the majority at about 3.5 years (breeding season), a seasonal influence was noted even in these precocious individuals. The TV rapidly increased from 4.2 to 4.6 years (breeding season), to produce the first peak in the graph, and then rapidly decreased to produce a trough at about 5 years (delivery season). Notably, the volume at the trough, the baseline volume (10.36 ml \pm 3.39 SD, $n=28$, for subjects aged from 4.90 to 5.10 years), was significantly greater than that at about

4 years of age (3.40 ml \pm 1.39 SD, $n=24$, for subjects aged from 3.90 to 4.10 years; $P < 0.01$ by t -test).

The testis increased again from the baseline at 5.0 years and achieved a peak of 40–60 ml in the breeding season, whereupon it rapidly decreased again to the trough at about 6.0 years of age in the delivery season. The baseline volume at that age was approximately 15 ml, about 5 ml greater than the previous trough. From 6 to 7 years of age, this seasonal cycle was repeated with greater amplitude, and the baseline volume increased further.

Age changes in TV in the five individuals observed longitudinally are shown in Fig. 2 where the abscissa represents age and calendar month. This graph shows that TV change with age was composed both of seasonal increases and decreases and overall growth. The amplitude of the seasonal cyclical change became greater with age. Because the cyclicity of all individuals was fairly well synchronized, the age change analyzed cross-sectionally




Fig. 2 Longitudinal age change of TV in five males, from 3 to 7 years of age, *top* for subjects born in 1992 and *bottom* for those born in 1993. *Abscissa* is the age and calendar month

tionally preserves the seasonal changes (see Fig. 1b). The dates at peak TV, however, differed somewhat between individuals. Two individuals, numbers 1459 and 1470, showed clear but small peaks in October of the year they were 3, indicating that they were precocious. Before 7 years, their ages at peak TV were slightly younger than those of the other three individuals. Thereafter, the ages of peak TV were similar for all five individuals.

In every individual, peak TV occurred between October and December and then the volume rapidly decreased to its baseline around April. The TV again gradually increased from April, but from mid-September

the velocity of increase accelerated until peak TV was reached.

Figure 3 shows the seasonal change of TV in adults of more than 7 years of age, but note that data were not available for every month. As shown by the polynomial regression curve, TV decreased from February to May or June and then it increased in autumn and winter. The maximum volume is about twice that of the minimum.

Testosterone secretion and TV: from the longitudinal analysis of the peri-adolescent period

Figure 4 depicts two examples showing typical relationships between the concentration of serum T (nanograms per milliliter) and TV. Individual 1412 (Fig. 4a)





Fig. 3 Seasonal change of TV in adults

shows a simple cyclical pattern with one peak and trough in secretion each year starting from the winter (breeding season) of 4 years of age (ca. 4.5 years). The

Fig. 4a, b Two typical examples showing the relationship between testosterone (T) secretion (dotted line) and TV change (solid line). a Simple pattern. b Complicated pattern showing secretion in summer



peak T concentration increased with age: around 4.2 ng/ml at about 4.5 years, 13.5 ng/ml at about 5.5 years, and 14.5 ng/ml at about 6.5 years. The T concentration started to increase rapidly in summer (June–September) and its decrease from the peak concentration was similarly rapid to reach baseline in January or February. The change in TV synchronized well with the T concentration profile, except for the first TV peak, which was later than the T peak by about 1.5 months. TV also started to increase rapidly from 4.5 years, which was concurrent with a rapid increase in T concentration. TV attained its adult mean volume at about 5.5 years of age.

In individual 1459 (Fig. 4b), T secretion occurred early in the year, in both summer and autumn, and there was more than one peak of secretion. At 3 years of age, this individual was clearly precocious to have experienced a significant peak in T secretion in October, with a peak concentration of 4.0 ng/ml, which is comparable to the first peak concentration in individual 1412 at about 4.5 years. Notably, TV temporarily increased in November. At 5 years, there were three peaks in T level, in June, August, and October, the highest of which occurred in August. TV gradually increased from June to August and then, from September, it rapidly increased to the maximum volume of this age, around 30 ml. Although the volume gradually decreased from its peak, it was still more than 20 ml at the end of December. The TV decreased to its baseline of about 10 ml in January and this volume was maintained through to July at 5 years of age.

In the breeding season at 5 years, there were two T peaks at the beginning of July and October, and the TV

attained a peak volume of around 35 ml, smaller than 40 ml, the median of adults. As TV matured only in the following breeding season, TV development in this individual was retarded. There was a lag (latency period) between T and TV in this individual in the breeding seasons from 3 to 5 years of age when the TV had not yet matured. Of interest is that monkeys reared in the same cage tended to exhibit similar seasonal patterns of TV and T level, that is, numbers 1428 and 1439 were similar to number 1412 and number 1470 was similar to number 1459.

Age change and seasonality of nipple volume

Nipple volume (NV) did not change between birth and 2.5 years (Fig. 5). The nipples grew rapidly from the breeding season of 3 years and matured either in the latter half of adolescence or in the young-adult stage (5–10 years of age). Basic statistics for adults (aged 10–25 years) were mean 4.82 ml (SD=3.60), median 3.21 ml, 10th and 90th percentiles 0.66 and 8.83 ml, respectively. Thus, the NV in adults was highly variable (Fig. 5a). In adults, there was no significant change in NV with age. Older individuals (≥ 25 years of age), however, tended to have smaller nipples, with an average of 1.18 ml (SD=0.96). The difference between means was significant ($P < 0.01$, *t*-test).

Figure 5b focuses on animals younger than 10 years. The nipple grows slowly from birth to 4 years, to reach a



maximum of 1.0 ml. Although some data points are larger than 2.0 ml, the majority fell within the range of 0.5–1.0 ml. A seasonal fluctuation in NV was not evident from this diagram.

We examined the longitudinal age changes in NV in the juvenile and adolescent periods, from 2 to 7 years of age (Fig. 6). With the exception of individual 1447, the graphs of the other nine animals displayed similar age and seasonal changes. The exceptional subject, number 1447, had large nipples that fluctuated unusually. Subject 1729 was precocious by about 6 months. Our subject females first gave birth between 5 and 6 years of age. The distortions to cyclicity caused by pregnancy and lactation are described later.

Change of NV in early adolescence is represented by the graphs of two typical examples (Fig. 7). Individual 1460 (Fig. 7a) displayed regular cyclicity, with almost the same heights of peak NV and the same amplitude of seasonal fluctuation at 3, 4, and 5 years of age.

Subject 1744's (Fig. 7b) peak NV increased greatly from the fourth to the fifth winter, almost doubling in size, and a seasonal change was also evident. Many of the other subjects exhibited trajectories similar to that of 1744, where the baseline volume increased from 4 years and the growth component was quite large. In the fifth winter, there were two additional peaks in NV both before and after the peak in January, and a NV of greater than 0.8 ml was maintained for nearly 6 months

Fig. 5a, b Plots of nipple volume (NV) against age in female Japanese macaques. **a** In adults from 10 to 25 years of age, median (line and diamonds at both ends), 10th and 90th percentiles (dotted lines and X at both ends) are superimposed. **b** Nipple change from juvenile to young adult stages. Smoothed curves connecting peaks and troughs are superimposed



The relationship between the P concentration profile and NV change

Figure 8 shows the P concentration profile and NV change in early adolescence (no. 1469). The first signif-




Fig. 6 Longitudinal age change of NV in ten females from 2 to 7 years of age. *Abscissa* is the age and calendar month. The *thick line*, *dotted thick line*, and *line with X* are the plots for subjects 1447, 1729, and 1469, respectively

icant P peak was found as late as 30 January at 3 years. There was only one peak in that season and NV increased to attain only a low peak, which occurred a little earlier than the P peak.

In the next breeding season, the P level had two major peaks, on 20 November and 18 December, and a smaller peak, little more than 1 ng/ml, occurred on 8 January. The NV started to increase from November and attained its peak in February. Although NV decreased from that peak to a trough in March, it had increased again, despite fluctuations, to 0.6 ml on 30 July. The increase in summer was not accompanied by P-level elevation.

In the third breeding season (at 5 years of age), the P level was slightly higher than 1 ng/ml in October, and then it suddenly increased to its peak on 12 November. We believe that the individual conceived around that date. The NV decreased in early autumn until the 3rd of September, but then it started to increase until around the time of conception.

We next examined the relationship between the concentration profile of P and change in NV in two examples from middle to late adolescence, that is, from 4 to 6 years of age (Fig. 9). Individual 1433 (Fig. 9a) experienced three P peaks in the winter when she was 4 years of age (5 December, 9 January, and 6 February), and following these, a lower peak was found on 14 March. In that same breeding season, we observed three peaks in NV on 20 November, 22 January, and 20 February. After the measurement on 18 December, we ought to

have taken measurements on 1 January, but we could do so only on 8 January. If we suppose that a peak occurred there, then a peak in P followed a peak in NV by a reasonably regular lag of about 2 weeks.

The next cycle was initiated in November, and the subject conceived at around the time of the first P peak. The NV and P concentration profile followed the pregnancy pattern that is outlined below.

Although subject 1447 was previously described as an exceptional, she did show another typical pattern of P secretion and NV change (Fig. 9b). In this animal's fourth year, NV increased with three peaks on 24 September, 23 October, and 4 December. The P peaks, however, occurred on 12 December and 9 January. At around the time of the first P peak, the subject was considered to have conceived. NV and P levels showed great fluctuations during pregnancy, and the increase in NV in autumn was not accompanied by a P-level increase.

After parturition, P concentration remained below detection level until the middle of November and then four peaks occurred on 4 and 25 December, 22 January, and 19 February. The NV also peaked four times at roughly monthly intervals, on 13 November, 10 December, 15 January, and 12 February. Considering the interval of measurement of both P concentration and NV, a 2-week lag appears reasonable. The average NV over the 4-month breeding season was about 1.80 ml, higher than the baseline volume of about 1.0 ml. The NV increased again from July to attain a peak on 9 September. Thus, NV increased from summer to autumn as it had when the animal was 4 years old. The P peak was found on 26 November and 24 December and the subject conceived at around the time of this second peak.

Fig. 7a, b Two examples showing the age change pattern of NV **a** for number 1460: a simple cyclic pattern where the baseline volume does not change with age, and **b** for number 1744: a pattern showing seasonal cyclicality and growth





Fig. 8 Age change of NV (*solid line*) and the secretion profile of progesterone (*P*, *dotted line*) in a female subject from the juvenile to the middle of her adolescent period. At 5 years of age this subject became pregnant. In the diagram, *C* (estimated conception), *B* (parturition), and the *thick line* (pregnancy) delineate the pregnancy-related changes



The influence of reproduction on NV; pregnancy pattern NV change over the period of pregnancy was examined using the P concentration profile for the determination of the day of conception (see Suzuki et al. 2000). The subject depicted in Fig. 8 exhibits the general trend. She conceived in November at 5 years of age and, at that time, NV was already on the increase, as it had been since summer. In many cases, the NV did not show any outstanding characteristics such as a peak or trough on the day of conception. From the P concentration profile,

we determined that many subjects conceived during the first or second peak of concentration.

After conception, although NV temporarily decreased, it gradually increased, despite fluctuations, with the advance of pregnancy (see the latter half of 5 years in Fig. 9a and the latter half of 4 years in Fig. 9b). The subject delivered around the time when NV had attained its maximum or second maximum peak in the birth season. After parturition, NV decreased slowly from spring to autumn with fluctuation until it started to follow the menstrual cycle. The concentration profile of